<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689221</url>
  </required_header>
  <id_info>
    <org_study_id>EMD 121974-011</org_study_id>
    <secondary_id>EORTC 26071-22072</secondary_id>
    <secondary_id>2007-004344-78</secondary_id>
    <nct_id>NCT00689221</nct_id>
  </id_info>
  <brief_title>Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status</brief_title>
  <acronym>CENTRIC</acronym>
  <official_title>Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational
      integrin inhibitor, cilengitide, in combination with standard treatment versus standard
      treatment alone in newly diagnosed glioblastoma subjects with a methylated
      O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor
      tissue.

      The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling
      element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be
      a predictive marker for benefit from temozolomide (TMZ) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) Time</measure>
    <time_frame>Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)</time_frame>
    <description>The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Time - Investigator and Independent Read</measure>
    <time_frame>Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)</time_frame>
    <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause. Investigator read is the assessment of all imaging by the treating physician at the local trial site and Independent Read is the assessment of all imaging centrally by an Independent Review Committee (IRC). Investigator's assessed progression according to MacDonald criteria and IRC by Response Assessment in Neuro-Oncology Working Group (RANO) criteria using Gadolinium-enhanced magnetic resonance imaging.
Investigator and IRC read: Progression is defined as greater than 25 percent increase in the sum of the product of the largest perpendicular diameters of enhancing tumor compared to the smallest prior sum, or Worsening of an evaluable lesion(s),or Marked increase in T2/FLAIR non-enhancing lesions (IRC only) or Any new lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 of Week -1</time_frame>
    <description>The Cmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 of Week -1</time_frame>
    <description>The Tmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose</measure>
    <time_frame>Day 1 of Week -1</time_frame>
    <description>The AUC (0-6) for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores</measure>
    <time_frame>Up to 50 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Brain Module (EORTC QLQ-BN20) Sub-scale Scores</measure>
    <time_frame>Up to 50 months</time_frame>
    <description>The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale ('1=not at all', '2=a little', '3=quite a bit' and '4=very much'), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5-Dimensions (EQ-5D) Questionnaire Index</measure>
    <time_frame>Up to 50 months</time_frame>
    <description>The EuroQuol-5D (EQ-5D) questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.594 (death) and the highest is 1.00 (full health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Work Status at End of Study</measure>
    <time_frame>Baseline, End of study (up to cut-off date, [19 Nov 2012])</time_frame>
    <description>Number of participants with change from baseline in work status (working full time [FT], part-time [PT], unemployed/retired [U/R]) at end of study (EOS) (up to cut-off date, [19 Nov 2012]) was reported. For the category 'part-time', the following sub-categories were defined: part-time due to basic disease (PT1); part-time not due to basic disease (PT2); part-time reason not known (PT3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment Related AEs of Grade 3 or 4</measure>
    <time_frame>Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)</time_frame>
    <description>An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent AEs are the events between first dose of study drug and up to 28 days after last dose of study treatment. A Serious AE is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-related AEs are the AEs which are suspected to be reasonably related to the study treatment (cilengitide, or radiotherapy, or temozolomide) as per investigator assessment. The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI−CTC Toxicity Grade 3 or 4</measure>
    <time_frame>Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)</time_frame>
    <description>Thromboembolic events (standardized MedDRA query [SMQ]) Grade 3 or 4 AEs encompassed hemiparesis and cerebrovascular accident, pulmonary embolism, and deep vein thrombosis. Thromboembolic events (SMQ) of any grade and of Grade 3 or 4 were generally more frequent in the Cilengitide + Temozolomide/Radiotherapy group than in the Temozolomide/Radiotherapy group but were still in the expected range of this patient population The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters</measure>
    <time_frame>Up to 50 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">545</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Cilengitide + Temozolomide + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide + Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilengitide</intervention_name>
    <description>Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.</description>
    <arm_group_label>Cilengitide + Temozolomide + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.</description>
    <arm_group_label>Cilengitide + Temozolomide + Radiotherapy</arm_group_label>
    <arm_group_label>Temozolomide + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.</description>
    <arm_group_label>Cilengitide + Temozolomide + Radiotherapy</arm_group_label>
    <arm_group_label>Temozolomide + Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Tumor tissue specimens from the glioblastoma surgery or open biopsy (formalin-fixed,
             paraffin-embedded block; stereotactic biopsy not allowed) must be available for MGMT
             status analysis and central pathology review

          2. Newly diagnosed histologically proven supratentorial glioblastoma (World Health
             Organization [WHO] Grade IV)

          3. Proven methylated MGMT gene promoter methylation status

          4. Available post-operative gadolinium-enhanced magnetic resonance imaging (Gd-MRI)
             performed within less than (&lt;) 48 hours after surgery (in case it was not possible to
             obtain a Gd-MRI within &lt;48 hours post surgery, a Gd-MRI is to be performed prior to
             randomization)

          5. Stable or decreasing dose of steroids for greater than or equal to (&gt;=) 5 days prior
             to randomization

          6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0-1

          7. Meets 1 of the following recursive partitioning analysis (RPA) classifications: Class
             III (Age &lt; 50 years and ECOG PS 0). Class IV (meeting one of the following criteria:
             a) Age &lt; 50 years and ECOG PS 1 or b) Age &gt;= 50 years, underwent prior partial or
             total tumor resection, mini mental state examination [MMSE] &gt;= 27). Class V (meeting
             one of the following criteria: a) Age &gt;= 50 years and underwent prior partial or total
             tumor resection, MMSE &lt; 27 or b) Age &gt;= 50 years and underwent prior tumor biopsy
             only)

          8. Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          1. Prior chemotherapy within the last 5 years

          2. Prior RTX of the head

          3. Receiving concurrent investigational agents or has received an investigational agent
             within the past 30 days prior to the first dose of cilengitide

          4. Prior systemic antiangiogenic therapy

          5. Placement of Gliadel® wafer at surgery

          6. Inability to undergo Gd-MRI.

          7. Planned surgery for other diseases

          8. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal
             ulcer, or esophageal ulcer) within 6 months of enrollment

          9. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or
             basal cell carcinoma of the skin, or subjects who have been free of other malignancies
             for &gt;= 5 years are eligible for this study

         10. History of coagulation disorder associated with bleeding or recurrent thrombotic
             events

         11. Clinically manifest myocardial insufficiency (New York Heart Association [NYHA] III,
             IV) or history of myocardial infarction during the past 6 months; uncontrolled
             arterial hypertension

         12. Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Stupp, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Lausanne Medical Center (CHUV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andriy Markivskyy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact U.S. Medical Information Located in</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center Located in</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.</citation>
    <PMID>25163906</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>August 28, 2014</results_first_submitted>
  <results_first_submitted_qc>October 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly diagnosed Glioblastoma (WHO Grade IV)</keyword>
  <keyword>Cilengitide</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First/last participant (informed consent): Sep 2008/Aug 2011. Clinical data cut-off: 19 Nov 2012, Study completion date: Aug 2013.</recruitment_details>
      <pre_assignment_details>Enrolled: 3471 screened for eligibility; 2926 excluded (mainly due to unmethylated O6-methylguanine-DNA methyltransferase status and non-fulfillment of inclusion or exclusion criteria), 545 participants randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cilengitide + Temozolomide + Radiotherapy</title>
          <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
        </group>
        <group group_id="P2">
          <title>Temozolomide + Radiotherapy</title>
          <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing at cut-off date</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all the participants who were randomized to study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Cilengitide + Temozolomide + Radiotherapy</title>
          <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
        </group>
        <group group_id="B2">
          <title>Temozolomide + Radiotherapy</title>
          <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="272"/>
            <count group_id="B2" value="273"/>
            <count group_id="B3" value="545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="11.00"/>
                    <measurement group_id="B2" value="56.0" spread="10.97"/>
                    <measurement group_id="B3" value="56.4" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) Time</title>
        <description>The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
        <time_frame>Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)</time_frame>
        <population>ITT population included all the participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Time</title>
          <description>The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
          <population>ITT population included all the participants who were randomized to study treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="23.8" upper_limit="28.8"/>
                    <measurement group_id="O2" value="26.3" lower_limit="23.9" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8623</p_value>
            <p_value_desc>P-value is not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.808</ci_lower_limit>
            <ci_upper_limit>1.291</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) Time - Investigator and Independent Read</title>
        <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause. Investigator read is the assessment of all imaging by the treating physician at the local trial site and Independent Read is the assessment of all imaging centrally by an Independent Review Committee (IRC). Investigator’s assessed progression according to MacDonald criteria and IRC by Response Assessment in Neuro-Oncology Working Group (RANO) criteria using Gadolinium-enhanced magnetic resonance imaging.
Investigator and IRC read: Progression is defined as greater than 25 percent increase in the sum of the product of the largest perpendicular diameters of enhancing tumor compared to the smallest prior sum, or Worsening of an evaluable lesion(s),or Marked increase in T2/FLAIR non-enhancing lesions (IRC only) or Any new lesion</description>
        <time_frame>Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)</time_frame>
        <population>ITT population included all the participants who were randomized to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) Time - Investigator and Independent Read</title>
          <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause. Investigator read is the assessment of all imaging by the treating physician at the local trial site and Independent Read is the assessment of all imaging centrally by an Independent Review Committee (IRC). Investigator’s assessed progression according to MacDonald criteria and IRC by Response Assessment in Neuro-Oncology Working Group (RANO) criteria using Gadolinium-enhanced magnetic resonance imaging.
Investigator and IRC read: Progression is defined as greater than 25 percent increase in the sum of the product of the largest perpendicular diameters of enhancing tumor compared to the smallest prior sum, or Worsening of an evaluable lesion(s),or Marked increase in T2/FLAIR non-enhancing lesions (IRC only) or Any new lesion</description>
          <population>ITT population included all the participants who were randomized to study treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PFS Time: Investigator read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="10.8" upper_limit="15.9"/>
                    <measurement group_id="O2" value="10.7" lower_limit="8.1" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS Time: Independent read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="8.2" upper_limit="13.4"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.9" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>The Cmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
        <time_frame>Day 1 of Week -1</time_frame>
        <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>The Cmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
          <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167363.2" spread="368301.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <description>The Tmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
        <time_frame>Day 1 of Week -1</time_frame>
        <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <description>The Tmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
          <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.029" spread="0.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose</title>
        <description>The AUC (0-6) for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
        <time_frame>Day 1 of Week -1</time_frame>
        <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose</title>
          <description>The AUC (0-6) for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1.</description>
          <population>Analysis population included all participants of &quot;Cilengitide + Temozolomide + Radiotherapy&quot; group who received at least 1 cilengitide dose with plasma concentration data available on Day 1 of Week -1. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295171.2" spread="198050.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores</title>
        <description>The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale.</description>
        <time_frame>Up to 50 months</time_frame>
        <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores</title>
          <description>The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale.</description>
          <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for the specified category.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Health Status (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.34" spread="25.58"/>
                    <measurement group_id="O2" value="55.43" spread="27.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.70" spread="33.01"/>
                    <measurement group_id="O2" value="67.46" spread="31.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.34" spread="37.31"/>
                    <measurement group_id="O2" value="56.34" spread="35.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.49" spread="30.58"/>
                    <measurement group_id="O2" value="67.00" spread="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning (n=70, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.05" spread="29.16"/>
                    <measurement group_id="O2" value="65.41" spread="31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Activity (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.34" spread="36.77"/>
                    <measurement group_id="O2" value="62.72" spread="35.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.37" spread="33.07"/>
                    <measurement group_id="O2" value="39.73" spread="29.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" spread="20.77"/>
                    <measurement group_id="O2" value="7.71" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.30" spread="29.40"/>
                    <measurement group_id="O2" value="24.37" spread="28.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.96" spread="28.09"/>
                    <measurement group_id="O2" value="13.04" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia (n=71, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.66" spread="30.01"/>
                    <measurement group_id="O2" value="20.51" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss (n=71, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.13" spread="30.47"/>
                    <measurement group_id="O2" value="15.94" spread="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.78" spread="28.02"/>
                    <measurement group_id="O2" value="13.98" spread="25.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea (n=70, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="18.48"/>
                    <measurement group_id="O2" value="4.35" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties (n=71, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.23" spread="31.53"/>
                    <measurement group_id="O2" value="22.94" spread="31.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Brain Module (EORTC QLQ-BN20) Sub-scale Scores</title>
        <description>The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale (‘1=not at all’, ‘2=a little’, ‘3=quite a bit’ and ‘4=very much’), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.</description>
        <time_frame>Up to 50 months</time_frame>
        <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Brain Module (EORTC QLQ-BN20) Sub-scale Scores</title>
          <description>The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale (‘1=not at all’, ‘2=a little’, ‘3=quite a bit’ and ‘4=very much’), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.</description>
          <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for the specified category.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Future Uncertainty (n=68, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.49" spread="29.70"/>
                    <measurement group_id="O2" value="39.31" spread="30.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disorder (n=68, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.99" spread="20.24"/>
                    <measurement group_id="O2" value="17.78" spread="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Dysfunction (n=68, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.45" spread="30.62"/>
                    <measurement group_id="O2" value="23.39" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication Deficit (n=68, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.14" spread="28.59"/>
                    <measurement group_id="O2" value="19.96" spread="27.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headaches (n=68, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.98" spread="32.50"/>
                    <measurement group_id="O2" value="21.71" spread="26.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizures (n=68, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="22.93"/>
                    <measurement group_id="O2" value="8.05" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (n=66, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.38" spread="33.71"/>
                    <measurement group_id="O2" value="35.25" spread="31.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Skin (n=68, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" spread="20.00"/>
                    <measurement group_id="O2" value="13.57" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hair Loss (n=66, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="22.55"/>
                    <measurement group_id="O2" value="15.12" spread="26.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness of Legs (n=67, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.38" spread="34.12"/>
                    <measurement group_id="O2" value="20.39" spread="28.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder Control (n=67, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.40" spread="29.67"/>
                    <measurement group_id="O2" value="10.20" spread="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol 5-Dimensions (EQ-5D) Questionnaire Index</title>
        <description>The EuroQuol-5D (EQ-5D) questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.594 (death) and the highest is 1.00 (full health).</description>
        <time_frame>Up to 50 months</time_frame>
        <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol 5-Dimensions (EQ-5D) Questionnaire Index</title>
          <description>The EuroQuol-5D (EQ-5D) questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.594 (death) and the highest is 1.00 (full health).</description>
          <population>ITT population included all the participants who were randomized to study treatment. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.598" spread="0.43"/>
                    <measurement group_id="O2" value="0.623" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Work Status at End of Study</title>
        <description>Number of participants with change from baseline in work status (working full time [FT], part-time [PT], unemployed/retired [U/R]) at end of study (EOS) (up to cut-off date, [19 Nov 2012]) was reported. For the category ‘part-time’, the following sub-categories were defined: part-time due to basic disease (PT1); part-time not due to basic disease (PT2); part-time reason not known (PT3).</description>
        <time_frame>Baseline, End of study (up to cut-off date, [19 Nov 2012])</time_frame>
        <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Work Status at End of Study</title>
          <description>Number of participants with change from baseline in work status (working full time [FT], part-time [PT], unemployed/retired [U/R]) at end of study (EOS) (up to cut-off date, [19 Nov 2012]) was reported. For the category ‘part-time’, the following sub-categories were defined: part-time due to basic disease (PT1); part-time not due to basic disease (PT2); part-time reason not known (PT3).</description>
          <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: FT, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: FT, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: FT, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: FT, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: FT, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT1, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT1, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT1, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT1, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT1, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT2, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT2, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT2, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT2, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT2, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT3, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT3, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT3, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT3, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PT3, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: U/R, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: U/R, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: U/R, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: U/R, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: U/R, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: FT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: PT1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: PT2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: PT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: U/R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missing, EOS: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment Related AEs of Grade 3 or 4</title>
        <description>An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent AEs are the events between first dose of study drug and up to 28 days after last dose of study treatment. A Serious AE is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-related AEs are the AEs which are suspected to be reasonably related to the study treatment (cilengitide, or radiotherapy, or temozolomide) as per investigator assessment. The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
        <time_frame>Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)</time_frame>
        <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment Related AEs of Grade 3 or 4</title>
          <description>An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent AEs are the events between first dose of study drug and up to 28 days after last dose of study treatment. A Serious AE is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-related AEs are the AEs which are suspected to be reasonably related to the study treatment (cilengitide, or radiotherapy, or temozolomide) as per investigator assessment. The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
          <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Related Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs with NCI−CTC toxicity Grade 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs of Grade 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI−CTC Toxicity Grade 3 or 4</title>
        <description>Thromboembolic events (standardized MedDRA query [SMQ]) Grade 3 or 4 AEs encompassed hemiparesis and cerebrovascular accident, pulmonary embolism, and deep vein thrombosis. Thromboembolic events (SMQ) of any grade and of Grade 3 or 4 were generally more frequent in the Cilengitide + Temozolomide/Radiotherapy group than in the Temozolomide/Radiotherapy group but were still in the expected range of this patient population The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
        <time_frame>Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)</time_frame>
        <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI−CTC Toxicity Grade 3 or 4</title>
          <description>Thromboembolic events (standardized MedDRA query [SMQ]) Grade 3 or 4 AEs encompassed hemiparesis and cerebrovascular accident, pulmonary embolism, and deep vein thrombosis. Thromboembolic events (SMQ) of any grade and of Grade 3 or 4 were generally more frequent in the Cilengitide + Temozolomide/Radiotherapy group than in the Temozolomide/Radiotherapy group but were still in the expected range of this patient population The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome.</description>
          <population>Safety population included all the participants who received any dose of study treatment that is Cilengitide, Temozolomide or Radiotherapy. According to trial design safety data in trial arms (Cilengitide vs Control) were collected based on different visit frequency and different safety surveillance period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SMQ:Thromboembolic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMQ: Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters</title>
        <time_frame>Up to 50 months</time_frame>
        <population>Any clinically significant abnormal ECG and lab finding was planned to be reported as AE only so they have been captured in the below mentioned adverse event section.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilengitide + Temozolomide + Radiotherapy</title>
            <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 Gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 was optional in participants without disease progression, If considered beneficial in the opinion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Temozolomide + Radiotherapy</title>
            <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters</title>
          <population>Any clinically significant abnormal ECG and lab finding was planned to be reported as AE only so they have been captured in the below mentioned adverse event section.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cilengitide + Temozolomide + Radiotherapy</title>
          <description>Cilengitide 2000 milligram (mg) twice weekly over 1 hour intravenous infusion from Weeks -1 to 77, Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. Continuation of cilengitide treatment after Week 77 will be optional in participants without disease progression, If cilengitide treatment considered beneficial in the opinion of the Investigator,</description>
        </group>
        <group group_id="E2">
          <title>Temozolomide + Radiotherapy</title>
          <description>TMZ 75 mg/m^2 administered intravenously once daily from Weeks 1 to 6, from Week 11 onward, TMZ was given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 and RTX at a dose of 2 Gy per fraction once daily, 5 days per week from Weeks 1 to 6 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FEBRILE BONE MARROW APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HAEMATOTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>H1N1 INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>WOUND ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BRAIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>OPEN WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RADIATION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RADIATION NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FIBRIN D DIMER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>METASTASES TO MENINGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEOPLASM RECURRENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEURILEMMOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>STATUS EPILEPTICUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CEREBRAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CEREBRAL VENTRICLE DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>FACIAL NERVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL DECOMPENSATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NORMAL PRESSURE HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PYRAMIDAL TRACT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>VISUAL FIELD DEFECT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DYSTHYMIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PERSONALITY CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>VOCAL CORD POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BLADDER CATHETERISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PALLIATIVE CARE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PELVIC VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>EMBOLISM VENOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>RADIATION SKIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All manuscripts and materials relating to Study shall be submitted to Sponsor at least 60 days prior to submitting/presenting and allow Sponsor 60 days for review. If Sponsor requests, any confidential information shall be removed. In multi-center study, any publication shall not be made before the first multi-center publication; provided, however, that if no multi-center publication is made within 1 year from database lock, then Site may publish individually in accordance with this provision.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

